You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

K-TAB Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do K-tab patents expire, and what generic alternatives are available?

K-tab is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in K-TAB is potassium chloride. There are two hundred and forty drug master file entries for this compound. Eighty-four suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for K-tab

A generic version of K-TAB was approved as potassium chloride by ACTAVIS LABS FL INC on April 10th, 2002.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for K-TAB?
  • What are the global sales for K-TAB?
  • What is Average Wholesale Price for K-TAB?
Summary for K-TAB
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 4
Raw Ingredient (Bulk) Api Vendors: 314
Patent Applications: 2,535
What excipients (inactive ingredients) are in K-TAB?K-TAB excipients list
DailyMed Link:K-TAB at DailyMed
Drug patent expirations by year for K-TAB

US Patents and Regulatory Information for K-TAB

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Abbvie K-TAB potassium chloride TABLET, EXTENDED RELEASE;ORAL 018279-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Abbvie K-TAB potassium chloride TABLET, EXTENDED RELEASE;ORAL 018279-002 Aug 1, 1988 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Abbvie K-TAB potassium chloride TABLET, EXTENDED RELEASE;ORAL 018279-003 Nov 25, 2013 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 3 of 3 entries

Market Dynamics and Financial Trajectory for K-TAB

Introduction

K-TAB, a prescription medication containing potassium chloride, is used to treat hypokalemia and other conditions related to potassium deficiency. Understanding the market dynamics and financial trajectory of K-TAB involves analyzing its usage, competition, pricing, and regulatory environment.

Medical Indications and Usage

K-TAB is indicated for the treatment of hypokalemia, including cases caused by diuretics, and for digitalis intoxication without AV block. It is available in sustained-release tablet form, providing 10mEq or 20mEq of potassium chloride per tablet[2][4].

Market Segment

K-TAB operates within the electrolyte supplement market, which is a niche but essential segment of the pharmaceutical industry. This market is driven by the need to manage and treat electrolyte imbalances, particularly in patients with chronic conditions or those undergoing certain medical treatments.

Competition

The electrolyte supplement market is relatively stable, with a few key players. K-TAB competes with other potassium chloride products, including generic versions and alternative formulations. The competition is primarily based on pricing, formulation, and brand reputation.

Pricing and Revenue

The pricing of K-TAB can vary depending on the region, insurance coverage, and the specific formulation. Generally, K-TAB is priced competitively with other potassium chloride products. For instance, the cost can range from a few dollars to over $10 per tablet, depending on the dosage and the pharmacy[4].

In terms of revenue, K-TAB generates significant income for its manufacturer, although it is not among the top-selling drugs globally. The revenue is steady due to the consistent demand for potassium chloride supplements in medical practice.

Regulatory Environment

K-TAB is a prescription-only medication, classified as a Schedule Rx drug. It is subject to various regulatory requirements, including monitoring of adverse reactions, clinical trials, and compliance with FDA guidelines. The regulatory environment is stringent, ensuring the safety and efficacy of the product[2][4].

Sales Performance

While K-TAB is not one of the top 10 best-selling drugs, it maintains a stable market presence. The overall pharmaceutical market has seen fluctuations, particularly with the impact of COVID-19 vaccines and treatments in recent years. However, niche products like K-TAB tend to have more stable sales trajectories due to their specific medical indications and consistent demand[3].

Financial Trajectory

The financial trajectory of K-TAB is characterized by steady sales and revenue. Here are some key points:

Revenue Stability

K-TAB's revenue is relatively stable due to its essential role in treating hypokalemia and other potassium-related conditions. This stability is less affected by broader market trends compared to blockbuster drugs.

Market Share

K-TAB holds a significant share in the potassium chloride supplement market, although the exact market share can fluctuate based on competition and new product entries.

Pricing Strategies

The pricing strategy for K-TAB is competitive, with the manufacturer aiming to balance profitability with patient affordability. Price adjustments are made in response to market conditions and competitor pricing.

Future Outlook

The future outlook for K-TAB is positive, driven by the ongoing need for potassium chloride supplements in medical practice. Advances in healthcare and an aging population are likely to sustain demand for this medication.

Patient and Physician Perspectives

Patient Compliance

Patient compliance with K-TAB is generally good due to its straightforward dosage regimen and the critical nature of treating hypokalemia. However, side effects such as gastrointestinal discomfort can affect compliance in some cases[2][4].

Physician Preference

Physicians often prefer K-TAB due to its established efficacy and safety profile. The sustained-release formulation helps in maintaining stable potassium levels, which is a key consideration in clinical practice.

Adverse Reactions and Safety Profile

K-TAB is associated with several adverse reactions, including hyperkalemia, gastrointestinal discomfort, and esophageal or GI ulceration. These risks are managed through careful monitoring and adherence to dosage guidelines[2][4].

Conclusion

K-TAB operates in a stable segment of the pharmaceutical market, driven by consistent medical need. Its financial trajectory is characterized by steady revenue and a competitive pricing strategy. While it is not a blockbuster drug, K-TAB remains an important medication for treating hypokalemia and other related conditions.

Key Takeaways

  • Stable Market Presence: K-TAB has a consistent market presence due to its essential role in treating hypokalemia.
  • Competitive Pricing: The pricing strategy is competitive, balancing profitability with patient affordability.
  • Regulatory Compliance: K-TAB is subject to stringent regulatory requirements to ensure safety and efficacy.
  • Steady Revenue: The revenue from K-TAB is relatively stable, less affected by broader market trends.
  • Patient and Physician Preference: K-TAB is preferred by both patients and physicians due to its efficacy and safety profile.

FAQs

What is K-TAB used for?

K-TAB is used to treat hypokalemia, including cases caused by diuretics, and for digitalis intoxication without AV block.

What are the common side effects of K-TAB?

Common side effects include hyperkalemia, gastrointestinal discomfort, diarrhea, and esophageal or GI ulceration.

How is K-TAB administered?

K-TAB should be taken with meals and a glass of water or other liquid. It should not be chewed or crushed.

Is K-TAB available in generic form?

Yes, K-TAB is available in generic form, which can affect its pricing and market share.

What are the contraindications for K-TAB?

Contraindications include hyperkalemia, chronic renal disease, acute dehydration, heat cramps, severe tissue destruction, adrenal insufficiency, and familial periodic paralysis[2][4].

Sources

  1. UNODC: Afghanistan's 'tablet K' – a forensic insight into an emerging synthetic drug market.
  2. eMPR: K-TAB Prescription & Dosage Information.
  3. Genetic Engineering and Biotechnology News: Top 10 Best Selling Drugs.
  4. DailyMed: K-TAB®(potassium chloride extended-release tablets, USP).
  5. GSK: Home.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.